Search
Huatai Securities: The AI Medical Industry Trend Accelerates
2025-04-16 /
Read about 0 minute
Author：小编
Huatai Securities' latest research report reveals that the U.S. Food and Drug Administration (FDA) intends to minimize animal testing in drug development and promote alternative methods, including AI-driven toxicity computational models. This policy update is anticipated to be finalized by 2026. This shift aims to expedite the integration of AI throughout the entire new drug development pipeline, thereby encouraging innovative pharmaceutical companies to bolster their investments in AI-based drug discovery platforms. Consequently, the "AI + Medical" sector is poised for substantial growth by 2025, and investors are advised to keep a close eye on pertinent investment opportunities.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
